Status | Study |
Recruiting |
Study Name: Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Condition: Endometrial Clear Cell Adenocarcinoma Endometrial Serous Adenoc Date: 2015-07-09 Interventions: Drug: Cisplatin Given IV |
Recruiting |
Study Name: Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2015-05-11 Interventions: Drug: Carboplatin Given IV |
Active, not recruiting |
Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Ovarian Date: 2014-12-09 Interventions: Drug: Cabozantinib S-malate Gi |
Recruiting |
Study Name: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Condition: Adult Glioblastoma Endometrial Clear Cell Adenocarcinoma Date: 2014-05-16 Interventions: Biological: Bevacizumab Given |
Recruiting |
Study Name: Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endomet Date: 2014-04-07 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Condition: Malignant Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Date: 2014-02-19 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Clear Cell Adenocarcinoma Date: 2014-02-14 Interventions: Drug: Carboplatin Given IV |
Active, not recruiting |
Study Name: Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Condition: Endometrial Clear Cell Adenocarcinoma Estrogen Receptor Negativ Date: 2014-02-07 Interventions: Drug: Dasatinib Given PO |
Recruiting |
Study Name: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Condition: Cervical Adenosarcoma Cervical Adenosquamous Carcinoma Cer Date: 2013-12-19 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Clear Cell Adenocarcinoma Date: 2013-09-03 Interventions: Drug: Akt Inhibitor GSK2141795 |